Research On X Company's Profit Model And Financial Evaluation

In today's society,as people pay more and more attention to their physical health,the demand for medical drugs is increasing,which makes many people realize that the pharmaceutical production industry will have good development prospects,resulting in more and more fierce competition in the entire pharmaceutical production industry,coupled with the government's increasing standardized management of the pharmaceutical production industry in recent years,the increasing supervision of the pharmaceutical market has also had a certain impact on the development of the pharmaceutical production industry.Therefore,if a pharmaceutical production company wants to continue to operate,it must choose a suitable profit model to ensure that the company can make profits and continue to operate under this profit model.To judge whether a company's profit model is appropriate,we can analyze it from the perspective of financial evaluation.This paper uses the literature research method,contrast analysis method and case analysis method to analyze the profit model of X company,which is a representative company in the pharmaceutical production industry.This paper first analyzes the constituent elements of X company's profit model,determines that X company's profit model is the whole industry chain mutual win mode,and then from the angle of financial evaluation,analyzes X company's profit model.Because the comparison analysis by selecting competitors can more effectively reflect the shortcomings of X company's profit model,so this paper selects a certain representative in the pharmaceutical production industry,and the profit model adopted is the product profit model of Jiangzhong pharmaceutical Co.,Ltd.and the brand profit model of Yunnan Baiyao Group Co.,Ltd.as comparative companies to conduct comparative analysis,to judge the shortcomings of the profit model adopted by X company's compared with the other two companies,and this proposes relevant improvements to improve the competitiveness and production capacity of X company's in the market,and hopes to provide some reference for other pharmaceutical production companies to improve their profit model and improve their production and operation capabilities.